Summary.-The production of carcinoembryonic antigen (CEA) by human breast cancer tissue has been studied in relation to the prognosis of patients with breast cancer. All of the patients were in a controlled trial of adjuvant chemotherapy for the treatment of operable breast cancer. CEA was studied in primary tumours and axillary node metastases from these patients using an immunoperoxidase (PAP) method. Sections of 290 primary carcinomas and 217 axillary metastases were examined for CEA. The CEA status of the primary tumours was of no value as a prognostic indicator nor in the selection of patients for chemotherapy. In contrast, patients could be divided into 3 groups on the basis of the CEA results in the axillary nodes. In one group, in which cases were strongly positive for CEA (24% of the total) the prognosis, as reflected by recurrence free survival, was relatively good and chemotherapy produced no further advantage. In another group in which cases were weakly positive for CEA (18% of the total) the prognosis was poor but chemotherapy produced significant improvement. In a third group, in which cases were negative for CEA (58% of the total) the prognosis was poor and was not improved by chemotherapy, at least in the short term. Thus, the CEA status of axillary metastases may be clinically useful.
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THE PRODUCTION of carcinoembryonic antigen (CEA) by human breast tumours has been studied extensively. Several reports have shown that serial measurements of CEA in the serum can help to monitor the clinical course of patients with breast cancer (Steward et al., 1974; Tormey et al., 1977; Falkson et al., 1978 Falkson et al., , 1979 Lamerz et al., 1980; Staab et al., 1980a) . However, serum measurements may be influenced by certain variables including the rate of production by tumour cells and factors influencing release of CEA into the circulation and excretion by the liver (Bivins et al., 1975; Zamcheck et al., 1975; Ellison et al., 1977; O'Brien et al., 1980 ). An alternative method of CEA detection, which is not subject to these variables, is by immunohistochemistry which permits precise localization of CEA within individual tumour cells. Although the disease cannot be monitored by this method, attempts have been made to correlate immunohistochemically demonstrable CEA with various prognostic parameters (Shousha & Lyssiotis, 1978; Shousha et al., 1979; Walker, 1980) . However, conflicting results have been obtained, probably attributable to differences in the characteristics of the CEA antiserum used in the immunohistochemical method (Walker, 1980) .
In the present study the CEA status of both primary and metastatic breast cancer, as demonstrated by an immunohistochemical (immunoperoxidase) technique, was correlated with the clinical course of patients entered into a controlled trial of * Present address: Christie Hospital and Holt Radium Institute, Manchester, 20. adjuvant chemotherapy for the treatment of operable breast cancer. The aim was to assess the value of CEA expression as a prognostic indicator and as a means of predicting which patients might benefit from adjuvant chemotherapy.
MATERIALS AND METHODS
Patients.-All patients included in the present study had been entered into a multicentre randomized controlled trial of adjuvant chemotherapy for operable breast cancer which was initiated by the West Midlands Oncology Association in 1977. The protocol for this trial has been described elsewhere (Morrison et al., 1981) . Simple mastectomy was performed and axillary node status determined by axillary node sampling.
The present study is concerned exclusively with axillary node positive patients. These patients were allocated at random to either surgery only ("control") or surgery plus chemotherapy ("treated") groups. The chemotherapy consisted of cyclophosphamide, methotrexate, 5 fluoro-uracil, vincristine and adriamycin (Table I ). This regimen of Other parameters.-In addition to immunoperoxidase staining for CEA, conventionally stained sections of the primary tumours were assessed for histological grade (Bloom & Richardson, 1957) . Also samples of primary tumour cytosols were analysed for oestrogen receptor content using the dextran-coated charcoal method.
Statistical methods.-Correlations between the CEA status and clinical course of patients were performed using life table analysis. The differences in disease free and actual survival between the various groups under study were demonstrated by using the Peto log-rank method (Peto et al., 1977) . For each comparison life tables were constructed and a logrank x2 statistic estimated. All other comparisons were performed using the conventional x2 test. A P-value of < 0.05 was taken to be statistically significant. RESULTS 
CEA staining in primary and metastatic breast cancer
Primary breast tumours from a total of 290 patients and axillary node secondaries from a total 217 patients were studied for CEA. Both primary and metastatic tumours were examined in 209 patients, the primary only in 81 patients and the axillary metastasis only in 8 patients. About one third of the primary tumours were strongly positive (+ +) for CEA whereas approximately one quarter of the metastic tumours were in this group (Table II) . There was concordance between CEA results in primary and secondary tissue in 71 % of cases.
There was no significant correlation between CEA status of either primary or secondary tissue and (i) menopausal The median duration of follow-up of the patients in this study was 2 years 7 months (range 9 months to 4 years 7 months). At this stage there was no significant difference in recurrence free survival between the control (surgery only) and the treated (surgery + chemotherapy) groups.
A. Primary tumours.-Recurrence-free survival of the control group of patients in which the primary tumours were negative or weakly positive for CEA (-/ +) was compared with that of control patients in which the primary tumours were strongly positive for CEA (+ +). There was no significant difference between the two groups (-/ + group, N = 92, R = 36; + + group, N=50, R=19; P=0.80). The group of patients that had received adjuvant chemotherapy was examined in the same way. There was again no significant difference between the two groups (-/ + group, N= 100, R = 38; + + group, N=48, R=15; P=0.51). free survival was significantly better for the CEA + + group than the CEA -/ + group ( Fig. 1 ; + + group, N=21, R=4;
-/+ group, N=78, R=38; P=0-036).
When the same data were analysed using actual survival there was a similar trend in favour of the group strongly positive for CEA but the difference was not significant (++ group, N=21, D=1; -/+ group, N=78, D=12; P=0.23). When the chemotherapy group of patients was analysed for recurrence free survival, no significant difference was evident (+ + group, N= 32, R = 13; + group, N= 86, R=31 ;P= 0.54).
CEA + + and CEA -/+ groups were then analysed separately according to treatment group. The results of comparison of recurrence-free survival of the treated and control subgroups of patients in the CEA -/ + category are shown in Fig. 2 . CEA -/ + patients in the treatment group fare significantly better than similar patients in the control group (treatment group, N = 86, R = 31; control group, N= 78, R= 38; P= 0.036). A similar trend was seen for actual survival but the difference was not significant (treatment group, N = 86, D = 6; control group, N=78, D=12; P=0.09). When the treated and control subgroups of patients in the CEA + + category were compared, there was no statistically significant difference in recurrence free survival (treatment group, N = 32, R = 13; control group, N=21, R=4;P=0417). ..In view of the significant difference in recurrence-free survival between the treatment and control subgroups of the CEA category, the two components of this rence-free survival was very significantly ry, i.e. -and +, were examined higher in the treatment group than the btely. Comparison of treatment and control group ( Fig. 3 ; treatment group, )1 groups that were negative for CEA N= 21, R= 3; control group, N = 18, d no significant difference (treat-R = 10; P = 0.005). When the same data were analysed using actual survival there was again a significant difference ( Fig. 4 The potential benefit of adjuvant chemotherapy has to be set against the cost of acute toxicity (Palmer et al., 1980) , the possibility of long-term organ damage and induction of second tumours (Reimer et al., 1977; Lerner, 1978; Valagussa et al., 1980) and economic factors. On the basis of present evidence it seems unlikely that adjuvant chemotherapy will be of equal benefit to all patients presenting with breast cancer. It is clear, therefore, that such treatment is only justifiable if it substantially improves prognosis and that there is a need for accurate discrimination between those patients who will and those who will not benefit from chemotherapy. In contrast, chemotherapy did result in significantly better recurrence free survival when given to patients whose nodal secondaries contained < 50 CEA-positive cells (i.e. the -/ + group) compared with the control group. Also when those patients with weakly positive results were examined in isolation, adjuvant chemotherapy was shown to produce a highly significant improvement in both recurrence-free survival and actual survival in comparison with the control group. However, no significant improvement in the prognosis of patients with CEA-negative nodal metastases was seen during this period of follow-up. From an assessment of inter-site variation in CEA expression (described under "assessment of sections") it is apparent that the negative and weakly positive groups are not entirely homogeneous. In some cases classed as having negative axillary metastases, more extensive sampling of nodes may have revealed other metastases that were weakly positive for CEA. Nevertheless these 2 categories of CEA results (-and +) in the axillary metastases, based on limited sampling (1-3 involved nodes), do seem to define groups of patients that behave differently in terms of their response to chemotherapy.
None of the significant differences discussed above could be explained by unequal representation of certain good prognostic features within the groups compared, including small size of primary tumour, good histological grade and the presence of oestrogen receptor in the primary tumour. Furthermore, since it has been shown that survival after local recurrence is longer than survival after distant metastasis (Karabali-Dalamaga et al., 1978) , the proportion of recurrences at each of these sites was determined in each of the groups. It was found, that in every group approximately two-thirds of recurrences were locoregional and one-third occurred at distant sites. Therefore, there is no reason to suspect that differences in mean duration of survival were produced by mal-distribution of any of these prognostic factors.
A possible explanation for the observed relationship between axillary node CEA status and prognosis and response to chemotherapy is suggested by data from in vitro studies (Drewinko & Yang, 1976 Ellison et al., 1977; Rutzky et al., 1979) . It has been shown that rapidly dividing tumour cells fail to produce CEA whereas cells in the stationary phase of growth are capable of CEA production. It could be argued, that axillary metastases which contain large numbers (i.e. > 5 %) of CEA-producing cells are associated with a favourable prognosis because a significant proportion of the metastatic cells are quiescent, the growth fraction is small and the growth rate of metastases is slow. This could explain the failure of chemotherapy to increase recurrence-free survival in this group, since most cytotoxic drugs have greater toxicity for rapidly proliferating cells (Madoc-Jones & Bruce, 1967; Goldenberg et al., 1971; Barranco & Novak, 1974; Twentyman & Bleehen, 1975) . Conversely, those patients with metastases that contain only a small proportion of CEA positive cells or none at all might be expected to have a worse prognosis because of the more aggressive nature of the tumour, and would be expected to show a good response to chemotherapy because of the larger proportion of dividing cells. Although, this proved true for patients with metastases that were weakly positive for CEA, there was no improvement in recurrence-free survival in CEAnegative cases. One possible interpretation is that the CEA-negative cases represent the most aggressive end of the spectrum of tumour growth and that chemotherapy was not capable of controlling the disease. 51 An alternative explanation of the findings is that CEA may induce an immune response and that this could affect the rate of progression of disease. However, the evidence for this is somewhat tenuous (Carrel et al., 1977; Hammarstrom et al., 1977; Kapsopoulou-Dominos & Anderer, 1979; Staab et al., 1980b) .
Whatever the explanation of these results, it does appear that the CEA status of axillary node metastases from patients with node-positive operable breast cancer may be of some clinical relevance in relation to prognosis and selection of patients for chemotherapy. The immunoperoxidase technique used throughout this study could be performed by any routine pathology laboratory and is relatively inexpensive. Clearly, it is important to repeat these analyses periodically as the duration of follow-up increases in order to determine whether the differences described above persist, and to detect any further trends that are not yet apparent which might be of clinical value.
